These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22487682)

  • 1. Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance.
    Ogawa T; Liggett TE; Melnikov AA; Monitto CL; Kusuke D; Shiga K; Kobayashi T; Horii A; Chatterjee A; Levenson VV; Koch WM; Sidransky D; Chang X
    Cell Cycle; 2012 Apr; 11(8):1656-63. PubMed ID: 22487682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AXL mediates resistance to cetuximab therapy.
    Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Luthar N; Toulany M; Gill PS; Salgia R; Kimple RJ; Wheeler DL
    Cancer Res; 2014 Sep; 74(18):5152-64. PubMed ID: 25136066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
    Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic down-regulation of death-associated protein kinase in lung cancers.
    Toyooka S; Toyooka KO; Miyajima K; Reddy JL; Toyota M; Sathyanarayana UG; Padar A; Tockman MS; Lam S; Shivapurkar N; Gazdar AF
    Clin Cancer Res; 2003 Aug; 9(8):3034-41. PubMed ID: 12912953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
    Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
    Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
    Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
    Yang B; Yang ZG; Gao B; Shao GG; Li GH
    Int J Clin Exp Pathol; 2015; 8(10):12961-6. PubMed ID: 26722491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells.
    Tanaka T; Bai T; Toujima S; Utsunomiya T; Matsuoka T; Kobayashi A; Yamamoto M; Sasaki N; Tanizaki Y; Utsunomiya H; Tanaka J; Yukawa K
    Oncol Rep; 2012 Apr; 27(4):1292-8. PubMed ID: 22246465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
    Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
    Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of methylation-associated silencing of the death-associated protein kinase gene on nasopharyngeal carcinoma.
    Kong WJ; Zhang S; Guo CK; Wang YJ; Chen X; Zhang SL; Zhang D; Liu Z; Kong W
    Anticancer Drugs; 2006 Mar; 17(3):251-9. PubMed ID: 16520653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
    Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
    BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.
    Tang X; Wu W; Sun SY; Wistuba II; Hong WK; Mao L
    Mol Cancer Res; 2004 Dec; 2(12):685-91. PubMed ID: 15634757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA content and methylation of p16, DAPK and RASSF1A gene in tumour and distant, normal mucosal tissue of head and neck squamous cell carcinoma patients.
    Laytragoon-Lewin N; Chen F; Castro J; Elmberger G; Rutqvist LE; Lewin F; Turesson I; Lundgren J
    Anticancer Res; 2010 Nov; 30(11):4643-8. PubMed ID: 21115918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
    Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
    Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
    Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J
    Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
    Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
    BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.